When considering why insulin-treated individuals have the poorest outcomes, it is important to highlight that our insulin-treated cohort was made of two distinct groups, those with type 1 diabetes and those with type 2 diabetes of longer duration who have failed to establish optimal glycaemic management with other therapies. The gene discussed is INS; the disease is type 2 diabetes mellitus.